Nonalcoholic fatty liver disease: current issues and novel treatment approaches. - Wikidata - wikimedia - TriplyDB

Nonalcoholic fatty liver disease: current issues and novel treatment approaches.

Nonalcoholic fatty liver disease: current issues and novel treatment approaches.

http://www.wikidata.org/entity/Q38074898

about

Identification of isosilybin a from milk thistle seeds as an agonist of peroxisome proliferator-activated receptor gamma Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions Mitochondrial Molecular Pathophysiology of Nonalcoholic Fatty Liver Disease: A Proteomics Approach Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway Non-alcoholic fatty liver disease: need for a balanced nutritional source Chronic stress induces steatohepatitis while decreases visceral fat mass in mice.MicroRNA-29a/b/c targets iNOS and is involved in protective remote ischemic preconditioning in an ischemia-reperfusion rat model of non-alcoholic fatty liver disease.Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation.Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus.Potential roles of glucagon-like peptide-1-based therapies in treating non-alcoholic fatty liver disease.Mitogen-activated protein kinase phosphatase 3 (MKP-3)-deficient mice are resistant to diet-induced obesity Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes.Non-alcoholic fatty liver disease in children: focus on nutritional interventions.Renal xenobiotic transporter expression is altered in multiple experimental models of nonalcoholic steatohepatitis.A 25-year-old woman with type 2 diabetes and liver disease.Thyroid hormone analogues and derivatives: Actions in fatty liver CIDEC/FSP27 is regulated by peroxisome proliferator-activated receptor alpha and plays a critical role in fasting- and diet-induced hepatosteatosis.Altered regulation of hepatic efflux transporters disrupts acetaminophen disposition in pediatric nonalcoholic steatohepatitis.Aronia melanocarpa Extract Ameliorates Hepatic Lipid Metabolism through PPARγ2 Downregulation.Drug disposition alterations in liver disease: extrahepatic effects in cholestasis and nonalcoholic steatohepatitis.Liver Cholesterol Overload Aggravates Obstructive Cholestasis by Inducing Oxidative Stress and Premature Death in Mice The Relationship between Intestinal Motility and Interstitial Cells of Cajal in Nonalcoholic Fatty Liver Mice.Modeling human nonalcoholic steatohepatitis-associated changes in drug transporter expression using experimental rodent models.Novel therapeutic targets for nonalcoholic fatty liver disease.Histologically proven non-alcoholic fatty liver disease and clinically related factors in recipients after liver transplantation.Potential approaches to ameliorate hepatic fat accumulation seen with MTP inhibition.Deferoxamine ameliorates hepatosteatosis via several mechanisms in ob/ob mice.Hedgehog inhibitors: a patent review (2013 - present).Endoplasmic reticulum stress and Oxidative stress in the pathogenesis of Non-alcoholic fatty liver disease.Effect of Liver Disease on Hepatic Transporter Expression and Function.Toxicogenomic module associations with pathogenesis: a network-based approach to understanding drug toxicity.Caffeine stimulates hepatic lipid metabolism by the autophagy-lysosomal pathway in mice.Insulin resistance: mechanism and implications for carcinogenesis and hepatocellular carcinoma in NASH.Beneficial effects of mineralocorticoid receptor blockade in experimental non-alcoholic steatohepatitis.Pharmacokinetic and safety evaluation of MB12066, an NQO1 substrate.Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.Nonalcoholic fatty liver disease: a frequent condition in type 2 diabetic patients.Amelioration of diet-induced steatohepatitis in mice following combined therapy with ASO-Fsp27 and fenofibrate.INFLUENCE OF OXIDATIVE STRESS AND OBESITY IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS.Concentration-dependent response to pioglitazone in nonalcoholic steatohepatitis.

P2860

Q24567657-ECE46AA0-48B9-4B8D-881E-FD12B27B9878 Q26751258-EFCEDF42-13D5-4F88-8247-A1050EA30D00 Q26753043-1C5B1610-9BB2-484B-8601-D09F551545FC Q26800894-3CF646A2-4DAC-40DB-A716-6942E98E3AC0 Q28248994-EDF9270F-6717-42C2-8296-AD1EF2A2EDC7 Q30436005-8234FFA7-D6EB-4D65-A7A3-E5D552B0DBD1 Q33599064-EA1690AB-8640-47A0-8245-9A1DF848C79E Q33755829-7F5470CD-39A9-4C06-8BAD-1D961EEEB902 Q33802278-2F3C54A5-99FB-4144-B59E-6E3E6C62ED49 Q33970970-DCC84195-9AD5-4CFB-BEEE-BA3A7F280DCB Q34077393-61D8B461-42EE-4BFA-AD5F-60F6470D7D57 Q34315432-F2E73335-BBDE-40AF-972D-609FF67EF4C0 Q34577949-E3EEA591-3D39-4D8B-8340-3A60FCDA3D21 Q34946039-EE06C336-A9B7-4174-B1A3-184D34FAA583 Q34975050-D638D69D-4EBE-43F2-A118-D977E637F281 Q35132642-2AC1B0BA-0FD7-42AF-994C-04A630C3A5E0 Q35224351-10D5F3E7-D4BD-4AA3-A3E2-B5273553EA7A Q35600259-D511DFDD-B5CF-4D62-BDC4-0791E0AAA532 Q36247589-DD641F03-DDAC-47E3-80DF-FCF00AB7206E Q36391044-2E0F304A-E8F7-48E5-850C-2E5D3544364E Q37231732-7BE97734-9580-4FBF-828F-DDE867882423 Q37347760-AFEF2720-AE94-4040-8786-2C9A90A46A2D Q37663390-B4A8A925-5E6B-4772-A6A6-BB328D48C79F Q38100206-D1633954-01BF-4507-A2B9-F2DDFD0395D9 Q38192013-4A6FA29F-3890-4CC7-8F82-44E8FF75CD0C Q38195808-219CD730-FF63-46B9-997C-A50AC960E1B9 Q38291587-C4F65D19-24E7-45AE-93E2-BC6EE887CA7F Q38366266-F99BDB0B-225F-42E8-B204-21AD12578FBB Q38557011-E48B8DC5-D123-41A4-9406-E4EBFD60543E Q38808182-B8DF0253-ECAF-4441-BDDD-236E2190C507 Q38821270-2FD7F0F1-377D-4BED-BFCA-0B8DB4A997F7 Q39113148-F1E128F2-DFA5-40BB-A968-50D4E3BC0C3F Q39304941-B64E3DD7-2E4D-4889-B3E6-289332A5F0AC Q41487407-D2D109E5-A0A0-411A-8CA5-7DB704B00F99 Q42736026-35726542-DD4D-467C-8B74-6371319D5443 Q43217282-44951FA4-933C-4EB5-AEBD-E3C5B544975F Q44407664-84A675DF-123C-4992-9962-EF5D0C732C67 Q47104903-0448EDD4-3EBB-4258-9C9C-A5D28030C00D Q47982951-7A3023B0-A266-4CEC-B03B-6A281F99E4AD Q48193707-3A02E5B9-04BD-4123-BF4F-8CD0A88399CF

P2860

Nonalcoholic fatty liver disease: current issues and novel treatment approaches.

http://www.wikidata.org/entity/Q38074898

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Nonalcoholic fatty liver disease: current issues and novel treatment approaches.

@en

type

label

Nonalcoholic fatty liver disease: current issues and novel treatment approaches.

@en

prefLabel

Nonalcoholic fatty liver disease: current issues and novel treatment approaches.

@en

P1433

Q38074898-C1CA08B4-E6EF-4D26-B870-FC94AE2932EA

P1476

Q38074898-4DF12796-AE51-4302-B9CF-ADD2DFE34513

P2093

Q38074898-5A7FE0A3-7822-48EF-96AC-4B13807DE163

Q38074898-6951BD5E-6AE3-4672-8AEB-F0E86CDDCE3B

Q38074898-8B2033F6-C23A-4FE9-A8B5-08F11E1DE532

Q38074898-A16C801E-2B61-4259-B4AB-65994AD96EDB

P2860

Q38074898-008125F4-5FEE-41AD-855A-7E8968463EE7

Q38074898-016C3E4F-312D-4E42-BB3C-B6C9A8D8B160

Q38074898-04B2BF4C-E772-4620-9997-CA5FB370BE8E

Q38074898-073A944E-B97D-4FF7-AD5C-BCA44193DE32

Q38074898-0BBA6C18-D876-4D7B-8C26-A0543F4D4D03

Q38074898-109093F6-B973-438E-9F66-35670192E745

Q38074898-11092A27-B188-46FE-9143-A807C634DC5E

Q38074898-128DDAF2-06B3-4DC9-BC9B-36AC4503AB5D

Q38074898-12A6FB59-F57E-4887-A092-560DE4FF6DB8

Q38074898-137A53D9-FD47-49B9-BABD-FD5FE2D75F22

P2888

Q38074898-23C1F0B2-C300-42B4-877F-106DA813B658

P304

Q38074898-F9558B76-25BA-4DE2-9A47-931ADE5DDBA4

P31

Q38074898-DD0354E8-1413-431E-980C-1DEA1F827FE1

P356

Q38074898-43E0BE7B-76B0-40BE-8AD7-2FD735066C1A

P433

Q38074898-F51CEE15-89CB-48FE-9295-B6DADD7735A9

P478

Q38074898-D4684725-4465-4F86-9E37-20301B8F7706

P577

Q38074898-C3EF91B1-AE21-4731-9D85-083552DFE37A

P6179

Q38074898-03244BFC-FAA8-44AA-985E-19C705859A8F

P698

Q38074898-98D54461-1CB6-4526-9271-7690EDDFECB0

P356

S40265-012-0004-0

P1433

P1476

Nonalcoholic fatty liver disease: current issues and novel treatment approaches.

@en

P2093

Fernando Bril

http://www.w3.org/2001/XMLSchema#string

Kenneth Cusi

http://www.w3.org/2001/XMLSchema#string

Nishanth E Sunny

http://www.w3.org/2001/XMLSchema#string

Romina Lomonaco

http://www.w3.org/2001/XMLSchema#string

P2860

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice

Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study

Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace

Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity

Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity

Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity

10-year follow-up of intensive glucose control in type 2 diabetes

The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

P2888

s40265-012-0004-0

P304

1-14

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40265-012-0004-0

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

73

http://www.w3.org/2001/XMLSchema#string

P577

2013-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1026815648

http://www.w3.org/2001/XMLSchema#string

P698

23329465

http://www.w3.org/2001/XMLSchema#string